caelyx pegylated liposomal 2 mg/ml concentrat pentru soluţie perfuzabilă
janssen pharmaceutica nv - doxorubicinum - concentrat pentru soluţie perfuzabilă - 2 mg/ml
leflunomide zentiva 10 mg comprimate
zentiva k.s. - leflunomidum - comprimate - 10 mg
leflunomide zentiva 20 mg comprimate filmate
zentiva k.s. - leflunomidum - comprimate filmate - 20 mg
elafra 20 mg comprimate filmate
rompharm company srl - leflunomidum - comprimate filmate - 20 mg
tyverb™ 250 mg comprimate filmate
novartis pharma ag - lapatinibum - comprimate filmate - 250 mg
b-mab 25 mg/ml concentrat pentru soluţie perfuzabilă
nativita srl - bevacizumabum - concentrat pentru soluţie perfuzabilă - 25 mg/ml
bevaas 100 25 mg/ml concentrat pentru soluţie perfuzabilă
m/s. hetero biopharma limited - bevacizumabum - concentrat pentru soluţie perfuzabilă - 25 mg/ml
bevaas 400 25 mg/ml concentrat pentru soluţie perfuzabilă
m/s. hetero biopharma limited - bevacizumabum - concentrat pentru soluţie perfuzabilă - 25 mg/ml
rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - agenți antineoplazici - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.
lextemy
mylan ire healthcare limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agenți antineoplazici - treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.